Nature.comTargeted therapies: Strategies for mature T cell cancersNature.comCancers of mature T cells, such as T cell non-Hodgkin lymphoma (NHL), are aggressive and resistant to treatment. Two new papers provide insight into the future treatment of mat… Continue reading
CBS PhillyGene Therapy Changes Life Of Star Singer Suffering From Childhood BlindnessCBS PhillyPHILADELPHIA (CBS) — On Tuesday the FDA approved a groundbreaking gene therapy treatment developed by doctors at the University of Pennsylvania. That same tr… Continue reading
Los Angeles Times |
FDA approves gene therapy to fix mutations that can lead to blindness
Los Angeles Times Tuesday’s announcement marks the third time in five months that the drug safety agency has allowed a gene therapy — a form of treatment with a long and fitful safety history — on the U.S. market. The first approval went to Kymriah, which treats a … After Decades, A Gene Therapy Is Approved. Next: The Debate On PriceForbes Gene therapy for rare form of blindness wins US approval – ABC NewsABC News FDA Approves First Gene Therapy Targeting Rare Form of Inherited BlindnessScientific American FDA.gov –MIT Technology Review –Chron.com all 65 news articles » |
Xconomy |
Andreessen Horowitz Backs Asimov’s Synthetic Biology CAD Software
Xconomy This week, it’s Asimov, another Boston-area synthetic bio startup, raising money. The amount—$4.7 million in seed funding—is much smaller than Ginkgo’s latest round, of course. But the investors are also noteworthy: Andreessen Horowitz, the well … |
Xconomy |
Andreessen Horowitz Backs Asimov’s Synthetic Biology CAD Software
Xconomy This week, it’s Asimov, another Boston-area synthetic bio startup, raising money. The amount—$4.7 million in seed funding—is much smaller than Ginkgo’s latest round, of course. But the investors are also noteworthy: Andreessen Horowitz, the well … |
|
Tiny stem cell companies close in on goals
NEWS.com.au Both have overcome major hurdles to manufacturing stem cell treatments on a large scale that are off-the-shelf products derived from healthy donor bone marrow and do not face immune system rejection issues. Australia’s Mesoblast, with a market value of … |
Jakarta Globe |
Tiny stem cell companies close in on goals
The Australian Athersys’s experimental Multistem treatment was one of the first companies to be designated by the US Food and Drug Administration as a promising cell-based therapy with potential to address unmet needs for serious or life-threatening conditions … Tiny Stem Cell Companies Close in on Major Heart Disease GoalsJakarta Globe |